Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: Report from the SENTRY antimicrobial surveillance program (1998)

Diagnostic Microbiology and Infectious Disease

Volumn 32, Issue 2, 1998, Pages 131-135

  Dipersio, Joseph R ^a   Jones, Ronald N ^b   Barrett, Timothy ^b   Doern, Gary V ^b   Pfaller, Michael A ^b  

^a AKRON CITY HOSPITAL   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CASE REPORT; HUMAN; IMMUNE DEFICIENCY; MALE; MORAXELLA CATARRHALIS; NONHUMAN; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; NEISSERIACEAE INFECTIONS; OFLOXACIN; PNEUMONIA, BACTERIAL; POPULATION SURVEILLANCE;

EID: 0031730271     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)00083-2     Document Type: Article

References (21)

1. Barry A.L., Pfaller M.A., Fuchs P.C., Packer R.R. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. medical centers in 1992 and 1993. Antimicrob Agents Chemother. 38:1994;2419-2425.
2. Berner R., Schumacher R.F., Brandis M., Forster J. Colonization and infection with Moraxella catarrhalis in childhood. Eur J Clin Microbiol Infect Dis. 15:1996;506-509.
3. Bolmstrom A, Arvidson S, Ericson M, Karlsson A (1988) A novel technique for direct quantification of antimicrobial susceptibility of microorganisms (abstr 1209). In: 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA. Washington, DC: American Society for Microbiology.
4. Brown B.A., Wallace R.J. Jr, Flanagan C.W., Wilson R.W., Luman J.I., Redditt S.D. Tetracycline and erythromycin resistance among clinical isolates of. Branhamella catarrhalis. Antimicrob Agents Chemother. 33:1989;1631-1633.
5. Brueggemann A.B., Kugler K.C., Doern G.V. In vitro activity of BAY12-8039, a novel 8-methoxyquinolone and six comparator fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and M. catarrhalis. Antimicrob Agents Chemother. 41:1997;1594-1597.
6. Cunliffe N.A., Emmanuel F.X.S., Thomson C.J. Lower respiratory tract infection due to ciprofloxacin-resistant. Moraxella catarrhalis. J Antimicrob Chemother. 36:1995;273-274.
7. Davies B.I., Maesen F.P.V. The epidemiology of respiratory tract pathogens in Southern Netherlands. Eur Respir J. 1:1988;415-420.
8. Doern G.V., Brueggemann A.B., Pierce G., Hogan T., Holley H.P. Jr, Rauch A. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995 results of a 30-center national surveillance study . Antimicrob Agents Chemother. 40:1996;2884-2886.
9. Groschel D.H.M. Moraxella catarrhalis and other Gram-negative cocci. Mandell G.L., Bennett J.E., Dolin R. Principles and Practice of Infectious DiseasesVol. 2. 4th ed. 1994;1926-1934 Churchill Livingstone, New York.
10. Jones R.N. Fluoroquinolone (lomefloxacin) international surveillance trial a report of 30 months of monitoring in vitro activity . Am J Med. 92:(suppl 4A):1992;S52-S57.
11. Jones R.N., Pfaller M.A., Doern G.V., Verhoef J., Jones M.E., Sader H.S. Initial report of longitudinal, international antimicrobial surveillance study (SENTRY): alarming resistance rates in monitored sites (68 medical centers) in the USA, Canada, South America, and Europe (abstr E-109). Proceedings of the 37th ICAAC. 1997;American Society for Microbiology, Washington, DC.
12. Kallings I. Sensitivity of Branhamella catarrhalis to oral antibiotics. Drugs. 31:1986;17-22.
13. Marchant C.D. Spectrum of disease due to Branhamella catarrhalis in children with particular reference to acute otitis media. Am J Med. 88:(suppl 5A):1990;15S-19S.
14. Standard Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically Approved standard M7-A4 . 4th edition. 1997;NCCLS, Wayne, PA.
15. Performance Standards for Antimicrobial Susceptibility Testing Approved Standard M100-S8 . 1998;NCCLS, Wayne, PA.
16. Robledano L., Rivera M.J., Otal I., Gomez-Lus R. Enzymatic modification of aminoglycoside antibiotics by Branhamella catarrhalis carrying an R factor. Drugs Exp Clin Res. 13:1987;137-143.
17. Slevin N.J., Aitken J., Thornley P.E. Clinical and microbiological features of Branhamella catarrhalis bronchopulmonary infections. Lancet. 1:1984;782-783.
18. Wallace R.J., Nash D.R., Steingrube V.A. Antibiotic susceptibilites and drug resistance in. Moraxella (Branhamella) catarrhalis. Am J Med. 88:(suppl 5A):1990;46S-50S.
19. Washington J.A. A multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens in the United States, 1992-1994. The Alexander Project. Diagn Microbiol Infect Dis. 25:1996;183-190.
20. Wood G.M., Johnson B.C., McCormack J.G. Moraxella catarrhalis: pathogenic significance in respiratory tract infections treated by community practitioners. Clin Infect Dis. 22:1996;632-636.
21. Zheng X. Beta-lactamase producing Branhamella in Beijing China (letter). Pediatr Infect Dis. 7:1988;744.